Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Overview 6 Therapeutics Development 7 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Stage of Development 7 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Therapy Area 8 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Indication 9 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Companies 12 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Universities/Institutes 14 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Companies Involved in Therapeutics Development 22 Arrien Pharmaceuticals, LLC 22 Bionomics Limited 23 Novartis AG 24 OncoTherapy Science, Inc. 25 Selvita S.A. 26 SignalChem Lifesciences Corp 27 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Drug Profiles 28 ARN-7016 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Drugs to Inhibit MELK for Solid Tumors - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 OTS-167 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 SEL-128 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecules to Inhibit MELK for Oncology - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecules to Inhibit MELK for Oncology - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Vaccine to Target FOXM1, MELK, HJURP, VEGFR-1 and VEGFR-2 for Ovarian Cancer - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Dormant Projects 36 Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Featured News & Press Releases 37 Mar 17, 2016: The Phase I clinical study of OTS167, MELK specific inhibitor, in Australia Completed 37 Feb 29, 2016: Publication of a paper describing the possible effect of a MELK inhibitor OTS167 on kidney cancer 37 Feb 26, 2016: Publication for possible biomarkers of OTS167, MELK inhibitor 38 Feb 12, 2016: Publication of a paper describing the possible effect of a MELK inhibitor, OTS167, on small cell lung cancer 38 Jan 25, 2016: The commencement of Phase I/II clinical study of OTS167, MELK specific inhibitor, for Acute Myeloid Leukemia patients in USA 38 Jan 05, 2016: MELK inhibitor, OTS167, Phase I clinical study commencement in Australia 39 Jun 18, 2015: The commencement of patient enrollment in Phase I clinical study of OTS167, a novel small molecule compound targeting cancer stem cells 39 Apr 15, 2013: Selvita Reports Data from SEL128 Oncology Program At AACR Annual Meeting 2013 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42

List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 21 Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 22 Pipeline by Bionomics Limited, H2 2016 23 Pipeline by Novartis AG, H2 2016 24 Pipeline by OncoTherapy Science, Inc., H2 2016 25 Pipeline by Selvita S.A., H2 2016 26 Pipeline by SignalChem Lifesciences Corp, H2 2016 27 Dormant Projects, H2 2016 36 List of Figures Number of Products under Development for, H2 2016 7 Number of Products under Development by Top 10 Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 11 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Actions, H2 2016 17 Number of Products by Routes of Administration, H2 2016 18 Number of Products by Stage and Routes of Administration, H2 2016 18 Number of Products by Molecule Types, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 20

Arrien Pharmaceuticals, LLC Bionomics Limited Novartis AG OncoTherapy Science, Inc. Selvita S.A. SignalChem Lifesciences Corp